Denali Therapeutics
Denali Therapeutics
DNLI
NASDAQ
15.33
USD
2.96%
About
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases and lysosomal storage disease. The Company has a portfolio of both small molecule and biotherapeutic medicines, comprising seven product candidates in clinical development across seven indications as well as preclinical therapeutic candidates.
Its three late-stage development programs include tividenofusp alfa (DNL310) for mucopolysaccharidosis II (MPS II); BIIB122/DNL151 (LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (eIF2B activator) for amyotrophic lateral sclerosis (ALS). SAR443820/DNL788 (RIPK1 inhibitor) is being evaluated in a Phase II study for multiple sclerosis (MS).
In addition, it has a Phase I/II study of TAK-594/DNL593 for frontotemporal dementia-granulin (FTD-GRN) and a Phase I/II study of DNL126 for MPS IIIA (Sanfilippo syndrome)..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 751.4K |
| Three Month Average Volume | 23.7M |
| High Low | |
| Fifty-Two Week High | 25.9 USD |
| Fifty-Two Week Low | 14.56 USD |
| Fifty-Two Week High Date | 26 Aug 2024 |
| Fifty-Two Week Low Date | 25 Apr 2024 |
| Price and Volume | |
| Current Price | 24.44 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 5.78% |
| Thirteen Week Relative Price Change | 23.03% |
| Twenty-Six Week Relative Price Change | 6.56% |
| Fifty-Two Week Relative Price Change | -15.53% |
| Year-to-Date Relative Price Change | -3.83% |
| Price Change | |
| One Day Price Change | 0.16% |
| Thirteen Week Price Change | 31.68% |
| Twenty-Six Week Price Change | 17.16% |
| Five Day Price Change | -1.33% |
| Fifty-Two Week Price Change | 5.85% |
| Year-to-Date Price Change | 13.89% |
| Month-to-Date Price Change | 0.29% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.44987 USD |
| Book Value Per Share (Most Recent Quarter) | 9.69128 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 7.44987 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 9.69128 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.27679 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 2.40612 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.00853 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.05717 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.85389 USD |
| Normalized (Last Fiscal Year) | -1.05717 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.05717 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.85389 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.05717 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.85389 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 7.47557 USD |
| Cash Per Share (Most Recent Quarter) | 6.26063 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.93541 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.7681 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.70712 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -72 |
| Cash Flow Revenue (Trailing Twelve Months) | -31,736 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -33,119.50% |
| Pretax Margin (Last Fiscal Year) | -43.93% |
| Pretax Margin (5 Year) | -104.51% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -59.51% |
| Operating Margin (Trailing Twelve Months) | -37,938.04% |
| Operating Margin (5 Year) | -115.73% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -43.94% |
| Net Profit Margin (Trailing Twelve Months) | -33,121.86% |
| Net Profit Margin (5 Year) | -104.50% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 5.22% |
| Tangible Book Value (5 Year) | 13.52% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -100.00% |
| Revenue Growth (3 Year) | 20.67% |
| Revenue Change (Trailing Twelve Months) | -99.63% |
| Revenue Per Share Growth | 11.53% |
| Revenue Growth (5 Year) | -0.51% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 30.70% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -145.08% |
| EPS Change (Trailing Twelve Months) | -163.84% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 3 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -896,044,000 |
| Net Debt (Last Fiscal Year) | -1,034,511,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 11 |
| Price to Sales (Trailing Twelve Months) | 2.8K |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 1.4K |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 412 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 3 |
| Price to Book (Most Recent Quarter) | 3 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 14 |
| Current Ratio (Most Recent Quarter) | 12 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -370,930,000 |
| Free Cash Flow (Trailing Twelve Months) | -402,099,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -11.11% |
| Return on Assets (Trailing Twelve Months) | -29.89% |
| Return on Assets (5 Year) | -14.98% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -14.01% |
| Return on Equity (Trailing Twelve Months) | -32.61% |
| Return on Equity (5 Year) | -20.47% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -13.37% |
| Return on Investment (Trailing Twelve Months) | -31.50% |
| Return on Investment (5 Year) | -17.71% |